| Remodelling the extracellular matrix in development and disease C Bonnans, J Chou, Z Werb Nature reviews Molecular cell biology 15 (12), 786-801, 2014 | 4121 | 2014 |
| Genomic hallmarks and structural variation in metastatic prostate cancer DA Quigley, HX Dang, SG Zhao, P Lloyd, R Aggarwal, JJ Alumkal, A Foye, ... Cell 174 (3), 758-769. e9, 2018 | 632 | 2018 |
| Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer YM Wu, M Cieślik, RJ Lonigro, P Vats, MA Reimers, X Cao, Y Ning, ... Cell 173 (7), 1770-1782. e14, 2018 | 477 | 2018 |
| GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression J Chou, JH Lin, A Brenot, J Kim, S Provot, Z Werb Nature cell biology 15 (2), 201-213, 2013 | 421 | 2013 |
| GATA3 in development and cancer differentiation: cells GATA have it! J Chou, S Provot, Z Werb Journal of cellular physiology 222 (1), 42-49, 2010 | 331 | 2010 |
| The DNA methylation landscape of advanced prostate cancer SG Zhao, WS Chen, H Li, A Foye, M Zhang, M Sjöström, R Aggarwal, ... Nature genetics 52 (8), 778-789, 2020 | 231 | 2020 |
| Transcription-associated cyclin-dependent kinases as targets and biomarkers for cancer therapy J Chou, DA Quigley, TM Robinson, FY Feng, A Ashworth Cancer discovery 10 (3), 351-370, 2020 | 182 | 2020 |
| microRNA-mediated regulation of the tumor microenvironment J Chou, P Shahi, Z Werb Cell cycle 12 (20), 3262-3271, 2013 | 162 | 2013 |
| Gigaxonin-controlled degradation of MAP1B light chain is critical to neuronal survival E Allen, J Ding, W Wang, S Pramanik, J Chou, V Yau, Y Yang Nature 438 (7065), 224-228, 2005 | 152 | 2005 |
| Zeppo1 is a novel metastasis promoter that represses E-cadherin expression and regulates p120-catenin isoform expression and localization EM Slorach, J Chou, Z Werb Genes & development 25 (5), 471-484, 2011 | 104 | 2011 |
| Clinical outcomes in cyclin-dependent kinase 12 mutant advanced prostate cancer MA Reimers, SM Yip, L Zhang, M Cieslik, M Dhawan, B Montgomery, ... European urology 77 (3), 333-341, 2020 | 87 | 2020 |
| HIF signaling in osteoblast-lineage cells promotes systemic breast cancer growth and metastasis in mice CS Devignes, Y Aslan, A Brenot, A Devillers, K Schepers, S Fabre, ... Proceedings of the National Academy of Sciences 115 (5), E992-E1001, 2018 | 87 | 2018 |
| MMP9 modulates the metastatic cascade and immune landscape for breast cancer anti-metastatic therapy M Owyong, J Chou, RJE van den Bijgaart, N Kong, G Efe, C Maynard, ... Life science alliance 2 (6), 2019 | 83 | 2019 |
| Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin CE Chu, M Sjöström, EA Egusa, EA Gibb, ML Badura, J Zhu, VS Koshkin, ... Clinical Cancer Research 27 (18), 5123-5130, 2021 | 82 | 2021 |
| The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression LE Littlepage, AS Adler, H Kouros-Mehr, G Huang, J Chou, SR Krig, ... Cancer discovery 2 (7), 638-651, 2012 | 80 | 2012 |
| Clinical and genomic implications of luminal and basal subtypes across carcinomas SG Zhao, WS Chen, R Das, SL Chang, SA Tomlins, J Chou, DA Quigley, ... Clinical cancer research 25 (8), 2450-2457, 2019 | 55 | 2019 |
| GATA3 targets semaphorin 3B in mammary epithelial cells to suppress breast cancer progression and metastasis P Shahi, CY Wang, J Chou, C Hagerling, H Gonzalez Velozo, ... Oncogene 36 (40), 5567-5575, 2017 | 49 | 2017 |
| MicroRNAs play a big role in regulating ovarian cancer–associated fibroblasts and the tumor microenvironment J Chou, Z Werb Cancer discovery 2 (12), 1078-1080, 2012 | 49 | 2012 |
| TROP2 expression across molecular subtypes of urothelial carcinoma and enfortumab vedotin-resistant cells J Chou, K Trepka, M Sjöström, EA Egusa, CE Chu, J Zhu, E Chan, ... European urology oncology 5 (6), 714-718, 2022 | 43 | 2022 |
| Efficacy of enfortumab vedotin in advanced urothelial cancer: analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study VS Koshkin, N Henderson, M James, D Natesan, D Freeman, A Nizam, ... Cancer 128 (6), 1194-1205, 2022 | 34 | 2022 |
